The Managed Care Review Board™ — Examining the Optimal Treatment, Care Management, and Benefit Designs for Major Depressive Disorder Web Activity

• Release Date: August 25, 2017
• Expiration Date: February 28, 2019
• Estimated Time to Complete Activity: 1.5 hours
• Compatible with all modern browsers and mobile devices

REVIEW BOARD FACULTY

Jeffrey Dunn, PharmD, MBA Vice President Clinical Strategy and Programs and Industry Relations MagellanRx Management Click here for biography Edmund Pezalla, MD, MPH CEO Enlightenment Bioconsult, LLC Click here for biography Fadia Tohme-Shaya, PhD, MPH Professor and Vice Chair for Academic Affairs University of Maryland School of Pharmacy Click here for biography Charles Raison, MD Mary Sue and Mike Shannon Chair for Healthy Minds, Children & Families Professor Human Development and Family Studies School of Human Ecology University of Wisconsin-Madison Professor Department of Psychiatry School of Medicine and Public Health University of Wisconsin-Madison Click here for biography

TARGET AUDIENCE

• Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
• Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for patients with major depressive disorder (MDD) including: physicians, pharmacists, registered nurses, and case managers

STATEMENT OF NEED/PROGRAM OVERVIEW

Major depressive disorder (MDD) is the second most common psychiatric disorder in the United States. It is a serious chronic medical illness that affects 6.7% of the United States (US) population each year. Women are 70% more likely than men to experience depression during their lifetime. Unlike normal emotional experiences of sadness, loss, or passing mood states, MDD is characterized by persistency: symptoms last for weeks or more, and significantly hinder daily functioning. There is no single cause of MDD; psychological, biological, genetic, and environmental factors contribute to its development. This activity will provide instruction on current and emerging treatment strategies, mental health benefit management, and patient care strategies for managed care professionals to use to improve overall health and economic outcomes for patients with MDD.

The educational format of The Managed Care Review Board™ will feature a multi-specialty, multi-professional faculty that collaborate, under the leadership of an Activity Chair, on the review of the clinical data, current guidelines, and economic data of a class of therapeutics. Similar to a mock pharmacy and therapeutics committee format, the program will include time for peer-to-peer discussion and debate among the diverse group of faculty members and the audience.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• Integrate recommendations from the APA Practice Guidelines with plan algorithms to ensure appropriate treatment and access to care for patients with MDD
• Employ optimal therapeutic and benefit management approaches to address the treatment gap created by low rates of remission for MDD patients within insured and/or managed populations
• Utilize data from current comparative effectiveness research and pharmacoeconomic models to make informed decisions that ensure appropriate access to optimal MDD therapies
• Implement decision-support systems and practice related tools to improve access and outcomes for patients with MDD

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Impact Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

	Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number – JA4008162-9999-18-153-H01-P

Type of Activity: Application

Continuing Nursing Education

Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This educational activity for 1.4 contact hours is provided by Postgraduate Institute for Medicine.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose. The Impact Education, LLC planners and managers have nothing to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period August 25, 2017, through February 28, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.